Horse Chestnut

Aesculus hippocastanum L. sits in Sapindaceae (the soapberry family; older books file it in Hippocastanaceae). NCBI Taxonomy treats it as taxon 43364; ITIS accepts TSN 28721. Linnaeus named it in Species Plantarum (1753); IPNI records the name as 781594-1. It is a large, fast deciduous tree: palmate leaves of five to seven toothed leaflets, sticky winter buds, and upright white panicles—the “candles”—with a yellow blotch that turns red as the flower is pollinated. The fruit is a spiny green capsule. Inside are one to three seeds, each with a large pale hilum scar. That seed is Hippocastani semen in European pharmacy, and it must comply with the Ph. Eur. seed monograph if it is going into a licensed extract.

Native range is the Balkan Peninsula. The tree was planted across temperate Europe and eastern North America as an ornamental. A later ecological footnote is the leaf miner Cameraria ohridella, which browns summer canopies but does not change the identity of the seed. Bark (Hippocastani cortex) is a separate EMA traditional-use monograph for heaviness of legs and hemorrhoid discomfort. Leaf and flower teas are folk objects, not the CVI evidence base.

Do not confuse this tree with sweet chestnut (Castanea sativa, Fagaceae), whose nuts are food. Do not treat Ohio buckeye (A. glabra) or California buckeye (A. californica) as interchangeable “horse chestnuts.” Those species are more often called buckeyes and are not the German CVI extract. Red horse chestnut (Aesculus × carnea) is an ornamental hybrid, not the trial material.

Chemistry splits the safety story. Escin (also spelled aescin) is the saponin mixture credited with venotonic and anti-edematous effects; β-escin is the form most discussed in pharmaceuticals. Esculin (aesculin) is a coumarin glycoside in raw seed and bark. Commercial HCSE is processed to strip the toxic coumarin load. A homemade decoction of backyard conkers is not that process.

The English name is a pile-up of folk etymology: a horseshoe-shaped scar on the fallen leaf, or the bitter seed once given to winded horses. Linnaeus’s 1753 diagnosis already nodded at a Turkish origin. Ottoman and Balkan plantings reached Vienna and then the rest of Europe as a street and estate tree. Britain made a children’s game of conkers. None of that is a food history. The seed is bitter, saponin-rich, and poisonous when eaten raw.

Nineteenth-century European pharmacy used bark and seed for venous complaints, hemorrhoids, and fever. The chemical turn is mid-twentieth century: escin was isolated in 1953, and German phytomedicine built delayed-release seed extracts (Venostasin and kin) standardized to aescin. That is when horse chestnut left the park and entered tablet bottles as a CVI drug class in Europe.

The trial that still gets cited in every review is Diehm, Trampisch, Lange, and Schmidt in The Lancet, 1996: oral HCSE versus compression stockings for CVI edema. Pittler and Ernst’s 1998 Archives of Dermatology systematic review, then their Cochrane reviews (including the 2012 update), assembled the randomized evidence. EMA’s Committee on Herbal Medicinal Products wrote a well-established-use monograph for specified ethanolic dry extracts of the seed (revision 1 adopted 15 January 2020) and a separate traditional-use file for bark.

In the United States the same plant is a dietary supplement, not a licensed CVI medicine. NCCIH’s consumer page (updated April 2025) records the 2012 evidence and the raw-plant toxicity. LiverTox (2018) records rare idiosyncratic hepatitis. History here is a pharmacognosy file, not a roasted-nut romance.

Escin is a mixture of acylated polyhydroxyoleanene saponins, not a single tablet molecule. Experimental work, reviewed by Sirtori (2001) and later by Gallelli (2019), points to three overlapping actions: venotonic effects (ion handling, including calcium sensitization of venous smooth muscle, and prostaglandin F2 release), anti-edematous effects (lower capillary filtration, protection of endothelial barrier function under hypoxia, including PECAM-1 distribution), and anti-inflammatory effects (reduced vascular permeability; antagonism to histamine and serotonin in older models). MSKCC notes inhibition of elastase and hyaluronidase as a proposed way of sparing capillary proteoglycans. EMA is blunter: the exact clinical mechanism is not known, but venous tone and capillary filtration are the working story.

The assay on the label changed. Older Ph. Eur. photometry declared standardized extracts at roughly 16–28% triterpene glycosides calculated as aescin, and the classic trial dose was 50 mg aescin twice daily (often 300 mg extract twice daily). In 2017 the Ph. Eur. switched to a more specific LC assay calculated as protoaescigenin. EMA’s well-established oral dose is now 21 mg protoaescigenin twice daily—the same product class, a different number. “50 mg aescin” on an old bottle and “21 mg protoaescigenin” on a new one are not two different herbs.

Esculin is not escin. Esculin is a hydroxycoumarin glycoside with anticoagulant folklore and real toxicity in unprocessed plant. LiverTox’s sentence that seeds contain “the toxic triterpene saponin known as escin and its glycoside esculin” conflates two chemistries. Follow the extract: processed HCSE is standardized to escin and depleted of the coumarin problem; raw seed is both saponin-bitter and coumarin-toxic.

Chronic venous insufficiency is the indication with a trial file. Pittler and Ernst’s Cochrane review (2012, CD003230) included seventeen randomized trials, all of extracts standardized to escin, lasting two to sixteen weeks. Versus placebo, HCSE reduced leg pain, edema, and pruritus; some trials also measured leg volume and circumference. Comparisons with O-β-hydroxyethyl rutosides, pycnogenol, or compression stockings generally found no large difference on pain, with pycnogenol ahead on edema in one trial. EMA’s HMPC used that systematic-review core to support well-established use for CVI symptoms: swollen legs, varicose veins, heaviness, pain, tiredness, itching, tension, and calf cramps. NCCIH’s 2025 reading is the same data with the same caveat: more rigorous, large-scale RCTs are still needed.

Diehm 1996 is the compression comparison people remember. It is one trial, not a reason to throw away stockings. Compression remains standard conservative care. An extract is an adjunct or an alternative when stockings are intolerable—not a clot treatment and not a substitute for ulcer care.

Hemorrhoids, phlebitis folklore, “male infertility” with varicocele, and topical gels for bruises sit on weaker or traditional ground. EMA traditional use covers cutaneous preparations for minor venous heaviness and for local edema/hematoma of bruises. That is long-standing use, not the CVI RCT stack. Do not treat a painful, thrombosed pile or a suspected DVT with a park-tree capsule.

Do not use horse chestnut to “detox veins,” to skip a vascular work-up, or as a food. The seed is not a roasted snack. The bark tea is not the Diehm extract.

Licensed European products: oral delayed- or immediate-release dry extracts of Hippocastani semen, ethanol 40–80% V/V, standardized to 6.5–10% triterpene glycosides as protoaescigenin (Ph. Eur.). EMA well-established posology in adults is 21 mg protoaescigenin twice daily. Benefit may take at least four weeks. Long-term use is possible only with a doctor. There is no relevant CVI indication in children under twelve, and use under eighteen is not recommended for lack of data.

Dietary supplements: capsules and tablets often still labeled to aescin (classically 50 mg twice daily). Quality varies. Look for a standardized seed extract, not “whole conker powder.” Gels and creams with aescin are the topical traditional form; EMA says not on broken skin, eyes, or mucous membranes.

Do not decoct fallen seeds, bark strips, or leaves. Do not inject anything. Parenteral sodium aescinate is a hospital product in some countries with a separate renal-injury file. It is not a supplement hack.

If someone and a clinician still consider a labeled course, the conservative pattern from trials is weeks of a standardized oral extract, not months of unlabeled “vein complex” blends, and not a substitution for compression, walking, or ulcer care. Stop for unexplained jaundice. Stop for sudden one-leg swelling and get examined.

Common with oral extracts: gastrointestinal upset, headache, vertigo, itching, and allergic reactions. EMA lists those with unknown frequency. Cochrane’s included trials reported the same cluster in a minority of participants; several trials reported no adverse events. Topical gels can itch or redden the skin.

Raw plant: nausea, vomiting, diarrhea, flushing, muscle twitching, incoordination, dilated pupils, and, in serious poisoning, paralysis or death—especially in children who eat conkers or in livestock. That is a poison-center problem, not “too strong a tea.”

Liver: rare. LiverTox’s likelihood score is D (possible, rare cause of clinically apparent injury). Published cases appeared after about four to eight weeks, hepatocellular or mixed, and were self-limited. A 2021 European case (Venenkraft) added another idiosyncratic report. There is no documented horse-chestnut acute liver failure in the LiverTox file. Jaundice still means stop the product and get labs. Some of the older tablet cases were multi-herb mixes (Venencapsan included celandine and others), so causality is not always clean.

Kidney: oral standardized extracts in CVI trials are not a nephrotoxin story. Intravenous aescin products have a different history. People with known renal insufficiency belong in the “see a doctor before any vein herb” bucket (EMA warning; MSKCC advises against use in compromised renal or hepatic function).

Do not eat raw seeds, bark, flowers, or leaves. Do not give conkers to children as food. Do not use extracts if you are allergic to Aesculus preparations.

EMA: do not use in pregnancy or while breastfeeding; safety is not established. Do not use oral CVI extracts as a pediatric product. If you have skin inflammation, thrombophlebitis, hard subcutaneous patches, severe pain, ulcers, sudden swelling of one or both legs, or known cardiac or renal insufficiency, see a doctor—those can be clots, ulcers, or organ failure, not “more aescin.”

MSKCC: skip horse chestnut products if kidney or liver function is compromised. LiverTox’s rare hepatitis is a reason for anyone with unexplained enzyme elevations to stay away.

CVI still needs a diagnosis. Horse chestnut is not a treatment for arterial claudication, unworked-up edema, or post-thrombotic syndrome on the basis of a rutoside Cochrane that did not show clear benefit (the comparison MSKCC flags). Compression, wound care, and indicated procedures remain the medical spine.

EMA’s well-established monograph lists no reported drug interactions for the specified oral seed extracts. That is a regulatory sentence, not a permission to hide the bottle from a pharmacist.

Bleeding: raw plant esculin has anticoagulant folklore, and aescin has been discussed for platelet effects in experimental work. US clinical summaries (MSKCC, consumer herb databases that NCCIH cites) still caution with anticoagulants and antiplatelets. If you take warfarin, DOACs, or dual antiplatelet therapy, this is a clinician conversation, not a stacking experiment.

Hypoglycemia is a theoretical older warning, not a robust interaction trial. Lithium and other narrow-index drugs have been named in secondary sources without a clean mechanistic file. Tell a pharmacist anyway.

Do not mix unlabeled “circulation” blends (horse chestnut plus butcher’s broom plus unidentified citrus bioflavonoids) and then blame the tree when something goes wrong. Combination products were already a confounder in some hepatotoxicity reports.